NDAORALCAPSULE
Approved
May 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLACIDYL (ethchlorvynol) is an oral sedative-hypnotic capsule approved in 1961 for the short-term treatment of insomnia and as a daytime sedative. The drug acts as a central nervous system depressant to promote sleep initiation. It represents a legacy small-molecule therapeutic from the pre-benzodiazepine era.
LOE Approaching
Late-lifecycle product with moderate competitive pressure (30/100) and likely declining sales trajectory; teams focused on retention and managed care optimization rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PLACIDYL offers minimal career growth potential given its approaching loss of exclusivity and declining market relevance. Roles are defensive and focused on legacy customer retention rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on PLACIDYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.